Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Ebba Bagge, Ulrica Beiron, Susanne Malander, Per Rosenberg & Elisabeth Åvall-Lundqvist. (2019) Pattern of endocrine treatment for epithelial ovarian cancer in the Southeast medical region of Sweden: a population-based study. Acta Oncologica 58:3, pages 320-325.
Read now
Read now
Articles from other publishers (33)
Zhiyong Yue, Shanhong He, Jinpei Wang, Qi Jiang, Hanping Wang, Jia Wu, Chenxi Li, Zixian Wang, Xuan He & Nannan Jia. (2023) Glyceollins from soybean: Their pharmacological effects and biosynthetic pathways. Heliyon 9:11, pages e21874.
Crossref
Crossref
Fulvio Borella, Stefano Fucina, Luca Mangherini, Stefano Cosma, Andrea Roberto Carosso, Jessica Cusato, Paola Cassoni, Luca Bertero, Dionyssios Katsaros & Chiara Benedetto. (2023) Hormone Receptors and Epithelial Ovarian Cancer: Recent Advances in Biology and Treatment Options. Biomedicines 11:8, pages 2157.
Crossref
Crossref
Tibor A. Zwimpfer, Ori Tal, Franziska Geissler, Ricardo Coelho, Natalie Rimmer, Francis Jacob & Viola Heinzelmann-Schwarz. (2023) Low grade serous ovarian cancer – A rare disease with increasing therapeutic options. Cancer Treatment Reviews 112, pages 102497.
Crossref
Crossref
Chun Wai Ng & Kwong-Kwok Wong. (2022) Impact of estrogen receptor expression on prognosis of ovarian cancer according to antibody clone used for immunohistochemistry: a meta-analysis. Journal of Ovarian Research 15:1.
Crossref
Crossref
Pamela M. J. McLaughlin, Maximilian Klar, Tibor A. Zwimpfer, Gilles Dutilh, Marcus Vetter, Christian Marth, Andreas du Bois, Carmen Schade-Brittinger, Alexander Reuss, Claudine Bommer, Christian Kurzeder & Viola Heinzelmann-Schwarz. (2022) Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial. BMC Cancer 22:1.
Crossref
Crossref
Marcus Vetter, Sylvia Stadlmann, Evelyne Bischof, Elena Laura Georgescu Margarint, Andreas Schötzau, Gad Singer, Viola Heinzelmann-Schwarz & Céline Montavon. (2022) Hormone Receptor Expression in Primary and Recurrent High-Grade Serous Ovarian Cancer and Its Implications in Early Maintenance Treatment. International Journal of Molecular Sciences 23:22, pages 14242.
Crossref
Crossref
Vallathol Dilip Harindran, V.P. Sanudev Sadanandan, P. Vishnu Sreedath, Parameswaran Prashanth, K.V. Sajeevan, P.S. Sreedharan & Narayanankutty Warrier. (2022) Therapy for Recurrent High-Grade Epithelial Ovarian Cancer—The Current Status and Future Trends. Indian Journal of Medical and Paediatric Oncology.
Crossref
Crossref
Lijun Tan, Katelyn Tondo-Steele, Caroline Foster, Carrie McIlwain, Danielle E. Bolland, Howard C. Crawford, Andrew Sciallis & Karen McLean. (2022) Inhibition of Tumor Microenvironment Cytokine Signaling Sensitizes Ovarian Cancer Cells to Antiestrogen Therapy. Cancers 14:19, pages 4675.
Crossref
Crossref
Rosa Montero-Macías, Pascal Rigolet, Elie Mikhael, Jonathan Krell, Vincent Villefranque, Fabrice Lecuru & Christina Fotopoulou. (2022) Traditional Systemic Treatment Options in Advanced Low-Grade Serous Ovarian Cancer after Successful Cytoreduction: A Systematic Review and Meta-Analysis. Cancers 14:15, pages 3681.
Crossref
Crossref
Lele Ye, Kan Pan, Su Fang, Su-Ni Wu, Su Chen, Sangsang Tang, Nan Wang, Haoke Zhang, Xinya Tong, Xinyu Shi, Shiyu Feng, Dan Xiang, Ruanmin Zou, Yingying Hu, Xiangyang Xue & Gangqiang Guo. (2022) Four Types of RNA Modification Writer-Related lncRNAs Are Effective Predictors of Prognosis and Immunotherapy Response in Serous Ovarian Carcinoma. Frontiers in Immunology 13.
Crossref
Crossref
Yuhan Wang, Haijian Zhou, Guanglei Zhong, Zhaojie Fu, Yu Peng & Tingting Yao. (2022) Development and Validation of a Nomogram to Predict the Probability of Venous Thromboembolism in Patients with Epithelial Ovarian Cancer. Clinical and Applied Thrombosis/Hemostasis 28, pages 107602962210955.
Crossref
Crossref
Olivier Trédan, Magali Provansal, Cyril Abdeddaim, Audrey Lardy-Cleaud, Anne-Claire Hardy-Bessard, Elsa Kalbacher, Anne Floquet, Laurence Venat-Bouvet, Alain Lortholary, Oana Pop, Jean-Sébastien Frenel, Mathilde Cancel, Rémy Largillier, Christophe Louvet, Benoît You, Alain Zannetti, Amelie Anota, Isabelle Treilleux, Daniel Pissaloux, Aurélie Houlier, Aude-Marie Savoye, Marie-Ange Mouret-Reynier, Jérôme Meunier, Charles-Briac Levaché, Fabien Brocard & Isabelle Ray-Coquard. (2022) Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR). Gynecologic Oncology 164:1, pages 18-26.
Crossref
Crossref
Giulia Scotto, Fulvio Borella, Margherita Turinetto, Valentina Tuninetti, Anna Valsecchi, Gaia Giannone, Stefano Cosma, Chiara Benedetto & Giorgio Valabrega. (2021) Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer. Cells 10:12, pages 3408.
Crossref
Crossref
Jun Xiong, Xiaoju He, Yuanyuan Xu, Wei Zhang & Fen Fu. (2021) MiR-200b is upregulated in plasma-derived exosomes and functions as an oncogene by promoting macrophage M2 polarization in ovarian cancer. Journal of Ovarian Research 14:1.
Crossref
Crossref
Phyllis van der Ploeg, Laura A. M. van Lieshout, Anja van de Stolpe, Steven L. Bosch, Marjolein H. F. M. Lentjes-Beer, Ruud L. M. Bekkers & Jurgen M. J. Piek. (2021) Functional estrogen receptor signaling pathway activity in high-grade serous ovarian carcinoma as compared to estrogen receptor protein expression by immunohistochemistry. Cellular Oncology 44:4, pages 951-957.
Crossref
Crossref
Robert L. Hollis, Barbara Stanley, John P. Thomson, Michael Churchman, Ian Croy, Tzyvia Rye, Clare Bartos, Fiona Nussey, Melanie Mackean, Alison M. Meynert, Colin A. Semple, Charlie Gourley & C. Simon Herrington. (2021) Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification. npj Precision Oncology 5:1.
Crossref
Crossref
Ya Gao, Kelu Yang, Shuzhen Shi, Jing Wang, Junhua Zhang & JinHui Tian. (2021) Tamoxifen and aromatase inhibitors for relapse of tubo-ovarian high-grade serous cancer. Cochrane Database of Systematic Reviews 2022:9.
Crossref
Crossref
Robbin Nameki, Heidi Chang, Jessica Reddy, Rosario I. Corona & Kate Lawrenson. (2021) Transcription factors in epithelial ovarian cancer: histotype-specific drivers and novel therapeutic targets. Pharmacology & Therapeutics 220, pages 107722.
Crossref
Crossref
Susanne Schüler-Toprak & Olaf Ortmann. (2021) Reproduktive Faktoren und das Ovarialkarzinomrisiko. Frauenheilkunde up2date 15:01, pages 43-61.
Crossref
Crossref
David M. Gershenson, Lauren P. Cobb & Charlotte C. Sun. (2020) Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for therelative efficacy of tamoxifen and aromatase inhibitors. Gynecologic Oncology 159:3, pages 601-603.
Crossref
Crossref
Simon P. Langdon, C. Simon Herrington, Robert L. Hollis & Charlie Gourley. (2020) Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer. Cancers 12:6, pages 1647.
Crossref
Crossref
Jacek P Grabowski, Clara Martinez Vila, Rolf Richter, Eliane Taube, Helmut Plett, Elena Braicu & Jalid Sehouli. (2020) Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer. International Journal of Gynecologic Cancer 30:4, pages 498-503.
Crossref
Crossref
Tova M. Bergsten, Joanna E. Burdette & Matthew Dean. (2020) Fallopian tube initiation of high grade serous ovarian cancer and ovarian metastasis: Mechanisms and therapeutic implications. Cancer Letters 476, pages 152-160.
Crossref
Crossref
Elena V. Tretyakova, Elena V. Salimova, Lyudmila V. Parfenova, Milyausha M. Yunusbaeva, Lilya U. Dzhemileva, Vladimir A. D’yakonov & Usein M. Dzhemilev. (2019) Synthesis of New Dihydroquinopimaric Acid Analogs with Nitrile Groups as Apoptosis-Inducing Anticancer Agents. Anti-Cancer Agents in Medicinal Chemistry 19:9, pages 1172-1183.
Crossref
Crossref
Lianyuan Tao, Haibo Yu, Yadong Dong, Guanjing Tian, Zhiyuan Ren & Deyu Li. (2019) Metastases with definitive pathological diagnosis but no detectable primary tumor: A surveillance epidemiology and end results‐based study. Cancer Medicine 8:13, pages 5872-5880.
Crossref
Crossref
You Zhou, Xiao Zheng, Bin Xu, Wenwei Hu, Tao Huang & Jingting Jiang. (2019) The Identification and Analysis of mRNA–lncRNA–miRNA Cliques From the Integrative Network of Ovarian Cancer. Frontiers in Genetics 10.
Crossref
Crossref
Sarah M. Temkin, Adrianne Mallen, Emily Bellavance, Lisa Rubinsak & Robert M. Wenham. (2018) The role of menopausal hormone therapy in women with or at risk of ovarian and breast cancers: Misconceptions and current directions. Cancer 125:4, pages 499-514.
Crossref
Crossref
Barbara Stanley, Robert L. Hollis, Hugo Nunes, Jonathan D. Towler, Xiangfei Yan, Tzyvia Rye, Carol Dawson, Melanie J. Mackean, Fiona Nussey, Michael Churchman, C. Simon Herrington & Charlie Gourley. (2019) Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors. Gynecologic Oncology 152:2, pages 278-285.
Crossref
Crossref
Charlie Gourley. (2019) Aromatase inhibition in ovarian cancer: repeated signals of efficacy but tools for patient selection remain elusive. Journal of Gynecologic Oncology 30:5.
Crossref
Crossref
Bastian Czogalla, Maja Kahaly, Doris Mayr, Elisa Schmoeckel, Beate Niesler, Thomas Kolben, Alexander Burges, Sven Mahner, Udo Jeschke & Fabian Trillsch. (2018) Interaction of ERα and NRF2 Impacts Survival in Ovarian Cancer Patients. International Journal of Molecular Sciences 20:1, pages 112.
Crossref
Crossref
Lydia Giannopoulou, Sophia Mastoraki, Paul Buderath, Areti Strati, Kitty Pavlakis, Sabine Kasimir-Bauer & Evi S. Lianidou. (2018) ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer. Gynecologic Oncology 150:2, pages 355-360.
Crossref
Crossref
T. A. Bogush, A. A. Basharina, E. A. Bogush, A. S. Tyulyandina, S. A. Tyulyandin & M. M. Davydov. (2017) Coexpression of estrogen receptors alpha and beta in serous ovarian cancer. Russian Journal of Biotherapy 16:4, pages 34-37.
Crossref
Crossref
Tea Lani?nik Ri?ner, Theresia Thalhammer & Csilla ?zvegy-Laczka. (2017) The Importance of Steroid Uptake and Intracrine Action in Endometrial and Ovarian Cancers. Frontiers in Pharmacology 8.
Crossref
Crossref